Intranasal Lidocaine Composition for Diverse Therapeutic Applications

Publication ID: 24-11857520_0002_PTD

Published: October 28, 2025

Category:New Applications & Use Cases

Legal Citation

pr1or.art Inc., “Intranasal Lidocaine Composition for Diverse Therapeutic Applications,” Published Technical Disclosure No. 24-11857520_0002_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857520_0002_PTD

This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,520.

Summary of the Inventive Concept

The present inventive concept expands the therapeutic scope of intranasal lidocaine compositions by applying the core technology to new fields, including respiratory diseases, ophthalmic disorders, hearing disorders, skin conditions, and gastrointestinal disorders.

Background and Problem Solved

The original patent disclosed a preservative-free intranasal composition of lidocaine for treating pain associated with tri-geminal neuralgia, facial neuropathic pain, and other conditions. However, this limited the composition's potential to address other significant health issues. The present inventive concept addresses this limitation by exploring new applications and use cases for the intranasal lidocaine composition.

Detailed Description of the Inventive Concept

The inventive concept comprises a preservative-free intranasal composition of lidocaine, administered via a mechanical pump metered dose spray device. This composition is adapted for treating a range of diseases and disorders, including asthma, chronic obstructive pulmonary disease (COPD), bronchiectasis, dry eye syndrome, tinnitus, Meniere's disease, otosclerosis, psoriasis, eczema, dermatitis, irritable bowel syndrome (IBS), Crohn's disease, and ulcerative colitis. The composition's ability to effectively deliver lidocaine to target sites enables its use in these new therapeutic areas.

Novelty and Inventive Step

The new claims introduce a significant inventive step by applying the core technology to entirely new fields, demonstrating a non-obvious expansion of the composition's therapeutic scope. The inventive concept's novelty lies in its ability to adapt the intranasal lidocaine composition for use in diverse therapeutic applications, addressing unmet needs in various industries.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept could include variations in the composition's formulation, such as different concentrations of lidocaine or the addition of other active ingredients. The mechanical pump metered dose spray device could also be modified or replaced with alternative delivery systems, such as nasal nebulizers or powder inhalers. These variations would ensure broad conceptual coverage and adaptability to different therapeutic contexts.

Potential Commercial Applications and Market

The inventive concept has significant commercial potential in various industries, including pharmaceuticals, ophthalmology, otolaryngology, dermatology, and gastroenterology. The expanded therapeutic scope of the intranasal lidocaine composition could lead to the development of new treatments and products, addressing unmet needs and improving patient outcomes in these fields.

CPC Classifications

Section	Class	Group
A	A61	A61K31/167
A	A61	A61K9/0043
A	A61	A61M11/00
A	A61	A61M2210/0618

Section 103 Obviousness Analysis (PHOSITA)

▼

Field of Art

Pharmaceutical drug delivery systems, specifically intranasal compositions with local anesthetic agents, focusing on metered-dose spray technologies for targeted therapeutic interventions

Person of Ordinary Skill (PHOSITA) Profile

A pharmaceutical formulation specialist with expertise in drug delivery systems, nasal spray technologies, and local anesthetic compositions, holding advanced degrees in pharmaceutical sciences or chemical engineering with knowledge of drug formulation, pharmacokinetics, and medical device design

Obviousness Rationale

A PHOSITA would recognize the inherent adaptability of the preservative-free intranasal lidocaine composition disclosed in the source patent, understanding that the core technological principles of targeted local anesthetic delivery could be systematically extended to multiple therapeutic domains by leveraging the established mechanical pump spray mechanism and lidocaine's pharmacological properties.

Obvious Combinations & Variations

Source Patent Element

Preservative-free intranasal lidocaine composition with mechanical multi-dose spray pump device

PTD Variation

Applying the same delivery mechanism to respiratory disease treatment via intranasal lidocaine

Obviousness Reasoning

Known technique of adapting established drug delivery systems to new therapeutic contexts, with predictable results based on lidocaine's established anti-inflammatory and local anesthetic properties

Source Patent Element

Targeted nasal spray for treating neuropathic pain conditions

PTD Variation

Extending intranasal lidocaine application to ophthalmologic and hearing disorder treatments

Obviousness Reasoning

Finite set of identifiable medical domains where local anesthetic and anti-inflammatory properties would provide therapeutic benefit, representing a logical extension of known pharmaceutical intervention strategies

Source Patent Element

Mechanical multi-dose nasal spray pump providing 0.04 ml to 0.2 ml volume doses

PTD Variation

Maintaining consistent dosage mechanism across diverse therapeutic applications including skin and gastrointestinal treatments

Obviousness Reasoning

Predictable engineering solution demonstrating that established drug delivery parameters can be consistently applied across different medical contexts with minimal reformulation

Source Patent Element

Locally active sodium channel blocker (lidocaine) in preservative-free formulation

PTD Variation

Expanding lidocaine's application from neuropathic pain to inflammatory conditions in multiple organ systems

Obviousness Reasoning

Well-understood pharmacological principle that a drug's mechanism of action can be systematically explored across related physiological domains using established delivery technologies

Source Patent Element

Intranasal administration targeting specific neurological pain conditions

PTD Variation

Translating intranasal delivery strategy to inflammatory and systemic disorder management

Obviousness Reasoning

Recognized pharmaceutical engineering approach of exploring alternative therapeutic applications for established drug delivery methodologies

35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857520 and the published technical disclosure, a person of ordinary skill in the art would find the expanded therapeutic applications of preservative-free intranasal lidocaine compositions to be obvious variations, rendering subsequent claims to such applications unpatentable under 35 U.S.C. § 103 due to the predictable extension of known pharmaceutical delivery technologies across related medical domains.

Original Patent Information

Patent Number	US 11,857,520
Title	Therapeutic composition of intranasal lidocaine
Assignee(s)	Nortic Holdings Inc.